San Francisco-based predictive health company Potrero Medical has closed $26.6 million in an oversubscribed Series C round, according to a statement from the company. The investment was led by GT Healthcare Capital Partners and Sonder Capital.
Potrero’s business is focused on employing smart sensors and data analytics to identify conditions in their early stages.
Its primary product is the Accuryn Monitoring System, a sensor-laden replacement for traditional urinary catheters that monitors vitals. Designed for intensive care units, the system collects and integrates measurements intra-abdominal pressure, urine output, and core body temperates
"At Potrero, we are not only focused on the 300,000 people that lose their life due to [acute kidney injury (AKI)], but also focused on their families. We have a technology that enables medical teams to proactively treat patients, so that patients can return to their normal lives with their families," Joe Urban, CEO of Potrero Medical, said in a statement. "We are thankful for the support of our investors and our shared commitment to transforming patient care through predictive health.”
According to a statement, the new funding will be used to develop an artificial intelligence and data analytics platform that would work alongside the Accuryn system to to facilitate early interventions prior to life-threatening events such as AKI. With this, Potrero’s technology aims to relieve the monitoring burden from physicians and nurses, as well as improve clinical outcomes among intensive care unit patients with AKI.
“As robotics advanced medicine by improving minimally invasive surgery, predictive health is revolutionizing the way physicians monitor and treat their patients.” Dr. Frederic Moll, CEO of Auris Health, founder of Intuitive Surgical, and a member of Potrero’s board, said in a statement. "Using artificial intelligence and data analytics, the Accuryn system will be a transformative advancement in predictive health.”